Email this article 
Post a Comment A fluorescent microspheres-based microfluidic test system for the detection of immunoglobulin G to SARS-CoV-2
- Authors: Shakurov R.I.1, Shansky Y.D.1, Prusakov K.A.1, Sizova S.V.1,2, Dudik S.P.1, Plotnikova L.V.3, Manuvera V.A.1, Klinov D.V.1, Lazarev V.N.1, Bespyatykh J.A.1,3, Basmanov D.V.1
-
Affiliations:
- Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine
- Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry
- Mendeleev University of Chemical Technology of Russia
- Issue: Vol 14, No 1 (2023)
- Pages: 44-53
- Section: Original Study Articles
- URL: https://bakhtiniada.ru/clinpractice/article/view/142803
- DOI: https://doi.org/10.17816/clinpract278280
- ID: 142803
Cite item
Full Text
Abstract
Background: The pandemic of the new coronavirus infection, COVID-19, is currently ongoing in the world. Over the years, the pathogen, SARS-CoV-2, has undergone a series of mutational genome changes, which has led to the spread of various genetic variants of the virus. Meanwhile, the methods used to diagnose SARS-CoV-2, to establish the disease stage and to assess the immunity, are nonspecific to SARS-CoV-2 variants and time-consumable. Thus, the development of new methods for diagnosing COVID-19, as well as their implementation in practice, is currently an important direction. In particular, application of systems based on chemically modified fluorescent microspheres (with a multiplex assay for target protein molecules) opens great opportunities.
Aim: development of a microfluidic diagnostic test system based on fluorescent microspheres for the specific detection of immunoglobulins G (IgG) to SARS-CoV-2.
Methods: A collection of human serum samples was characterized using enzyme-linked immunosorbent assay (ELISA) and commercially available reagent kits. IgG to SARS-CoV-2 in the human serum were detected by the developed immunofluorescent method using microspheres containing the chemically immobilized RBD fragment of the SARS-CoV-2 (“Kappa” variant) viral S-protein.
Results: The level of IgG in the blood serum of recovered volunteers was 9-300 times higher than that in apparently healthy volunteers, according to ELISA (p<0.001). Conjugates of fluorescent microspheres with the RBD-fragment of the S-protein, capable of specifically binding IgG from the blood serum, have been obtained. The immune complexes formation was confirmed by the fluorescence microscopy data; the fluorescence intensity of secondary antibodies in the immune complexes formed on the surface of microspheres was proportional to the content of IgG (r 0.963). The test system had a good predictive value (AUC 70.3%).
Conclusion: A test system has been developed, based on fluorescent microspheres containing the immobilized RBD fragment of the SARS-CoV-2 S-protein, for the immunofluorescent detection of IgG in the human blood serum. When testing the system on samples with different levels of IgG to SARS-CoV-2, its prognostic value was shown. The obtained results allow us to present the test system as a method to assess the level of immunoglobulins to SARS-CoV-2 in the human blood serum for the implementation in clinical practice. The test system can also be integrated into various microfluidic systems to create chips and devices for the point-of-care diagnostics.
Full Text
##article.viewOnOriginalSite##About the authors
Ruslan I. Shakurov
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine
Author for correspondence.
Email: ruslan.shakurov@rcpcm.org
ORCID iD: 0000-0002-5986-0676
SPIN-code: 9576-8093
Junior Research Associate
Russian Federation, 1a Malaya Pirogovskaya street, 119435 MoscowYaroslav D. Shansky
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine
Email: yar.shansky@rcpcm.org
ORCID iD: 0000-0003-4672-2474
SPIN-code: 7640-5940
PhD, Research Associate
Russian Federation, 1a Malaya Pirogovskaya street, 119435 MoscowKirill A. Prusakov
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine
Email: k.prusakov@rcpcm.org
ORCID iD: 0000-0002-7244-5741
SPIN-code: 9244-6581
Research Associate
Russian Federation, 1a Malaya Pirogovskaya street, 119435 MoscowSvetlana V. Sizova
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine; Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry
Email: sv.sizova@gmail.com
ORCID iD: 0000-0003-0846-4670
SPIN-code: 4322-1945
PhD, Research Associate
Russian Federation, 1a Malaya Pirogovskaya street, 119435 Moscow; MoscowStepan P. Dudik
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine
Email: stepan.dudik@rcpcm.org
ORCID iD: 0000-0002-3157-5902
SPIN-code: 8007-1870
Russian Federation, 1a Malaya Pirogovskaya street, 119435 Moscow
Lyudmila V. Plotnikova
Mendeleev University of Chemical Technology of Russia
Email: ntmdfs@gmail.com
Russian Federation, Moscow
Valentin A. Manuvera
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine
Email: vmanuvera@yandex.ru
ORCID iD: 0000-0002-2471-0563
SPIN-code: 9010-4521
PhD, Senior Research Assistant
Russian Federation, 1a Malaya Pirogovskaya street, 119435 MoscowDmitry V. Klinov
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine
Email: klinov.dmitry@mail.ru
ORCID iD: 0000-0001-8288-2198
SPIN-code: 9830-8561
PhD
Russian Federation, 1a Malaya Pirogovskaya street, 119435 MoscowVassili N. Lazarev
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine
Email: lazar0@mail.ru
ORCID iD: 0000-0003-0042-966X
SPIN-code: 1578-8932
PhD
Russian Federation, 1a Malaya Pirogovskaya street, 119435 MoscowJulia A. Bespyatykh
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine; Mendeleev University of Chemical Technology of Russia
Email: JuliaBes@rcpcm.org
ORCID iD: 0000-0002-4408-503X
SPIN-code: 6003-9246
PhD
Russian Federation, 1a Malaya Pirogovskaya street, 119435 Moscow; MoscowDmitriy V. Basmanov
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine
Email: dmitry.basmanov@rcpcm.org
ORCID iD: 0000-0001-6620-7360
SPIN-code: 1801-6408
Research Associate
Russian Federation, 1a Malaya Pirogovskaya street, 119435 MoscowReferences
- World Health Organization. Tracking SARS-CoV-2 variants [cited 2023 February, 20]. Режим доступа: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. Дата обращения: 20.02.2023.
- Баклаушев В.П., Юсубалиева Г.М., Бычинин М.В., и др. Рациональная стратегия поддержания противовирусного иммунитета к новым вариантам SARS-CoV-2 // Клиническая практика. 2022. Т. 13, № 3. С. 43–55. [Baklaushev VP, Yusubalieva GM, Bychinin MV, et al. A rational strategy for the maintenance of antiviral immunity to new SARS-CoV-2 strains. Journal of Clinical Practice. 2022;13(3):43–55. (In Russ).] doi: 10.17816/clinpract111120
- Fernandes RS, de Oliveira Silva J, Gomes KB, et al. Recent advances in point of care testing for COVID-19 detection. Biomed Pharmacother 2022;153:113538. doi: 10.1016/J.BIOPHA.2022.113538
- Filchakova O, Dossym D, Ilyas A, et al. Review of COVID-19 testing and diagnostic methods. Talanta 2022;244:123409. doi: 10.1016/J.TALANTA.2022.123409
- Farmer S, Razin V, Peagler AF, et al. Don’t forget about human factors: Lessons learned from COVID-19 point-of-care testing. Cell Reports Methods 2022;2:100222. doi: 10.1016/J.CRMETH.2022.100222
- Zhong Z, Wang J, He S, et al. An encodable multiplex microsphere-phase amplification sensing platform detects SARS-CoV-2 mutations. Biosens Bioelectron. 2022;203:114032.
- Патент РФ № RU 200301 U1/2020.10.15. Прусаков К.А., Басманов Д.В., Алдаров К.Г., и др. Микрофлюидный чип для проведения многопараметрического иммуноанализа. [Patent RUS № RU 200301 U1/2020.10.15. Prusakov KA, Basmanov DV, Aldarov KG, et al. Microfluidic chip for multiparametric immunoassay. (In Russ).] Режим доступа: https://yandex.ru/patents/doc/RU200301U1_20201015. Дата обращения: 20.02.2023.
- Yuan H, Chen P, Wan C, et al. Merging microfluidics with luminescence immunoassays for urgent point-of-care diagnostics of COVID-19. TrAC Trends Anal Chem 2022; 157:116814. doi: 10.1016/J.TRAC.2022.116814
- Sheridan C. Fast, portable tests come online to curb coronavirus pandemic. Nat Biotechnol 2020;38:515–518. doi: 10.1038/D41587-020-00010-2
- Drain PK, Ampajwala M, Chappel C, et al. A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagnosis of acute COVID-19 at the point of care: A clinical performance study. Infect Dis Ther. 2021;10:753–761. doi: 10.1007/S40121-021-00413-X/FIGURES/2
- Chen R, Ren C, Liu M, et al. Early detection of SARS-CoV-2 seroconversion in humans with aggregation-induced near-infrared emission nanoparticle-labeled lateral flow immunoassay. ACS Nano. 2021;15:8996–9004. doi: 10.1021/ACSNANO.1C01932
- Zhou Y, Chen Y, Liu W, et al. Development of a rapid and sensitive quantum dot nanobead-based double-antigen sandwich lateral flow immunoassay and its clinical performance for the detection of SARS-CoV-2 total antibodies. Sensors Actuators B Chem 2021;343:130139. doi: 10.1016/J.SNB.2021.130139
- Hajazadeh F, Khanizadeh S, Khodadadi H, et al. SARS-COV-2 RBD (Receptor binding domain) mutations and variants (A sectional-analytical study). Microb Pathog 2022;168:105595. doi: 10.1016/J.MICPATH.2022.105595
- Heggestad JT, Kinnamon DS, Olson LB, et al. Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test. Sci Adv 2021;7:4901–4926. doi: 10.1126/SCIADV.ABG4901/SUPPL_FILE/ABG4901_SOURCE_DATA.XLSX
- Gan HH, Zinno J, Piano F, Gunsalus KC. Omicron spike protein has a positive electrostatic surface that promotes ACE2 recognition and antibody escape. Front Virol 2022;2:43. doi: 10.3389/FVIRO.2022.894531
Supplementary files
